These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
833 related articles for article (PubMed ID: 20470296)
1. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort. Yong K; Kairaitis L Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296 [TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178 [TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of a team-led treatment protocol for the management of renal anaemia. Kotwal SS; Lan P; MacLeod A; Jardine M; Snelling P; Craig J; Cass A; Gallagher M Nephrology (Carlton); 2013 Oct; 18(10):649-54. PubMed ID: 23889845 [TBL] [Abstract][Full Text] [Related]
4. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare? Pussell BA; Walker R; Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333 [TBL] [Abstract][Full Text] [Related]
5. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres. Perrinet M; Décaudin B; Champs BB; Heran I; Urbina MA; Lemaitre V; Azar R; Odou P J Clin Pharm Ther; 2010 Aug; 35(4):395-400. PubMed ID: 20831542 [TBL] [Abstract][Full Text] [Related]
6. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198 [TBL] [Abstract][Full Text] [Related]
7. [Current issues in erythropoietin therapy of renal anemia]. Zakar G Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596 [TBL] [Abstract][Full Text] [Related]
8. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients. Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014 [TBL] [Abstract][Full Text] [Related]
9. Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron. Kapoian T Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S21-8. PubMed ID: 19010258 [TBL] [Abstract][Full Text] [Related]
10. ORAMA: a study to investigate EBPG impact on renal anaemia - design and baseline data. Locatelli F; Covic A; Macdougall IC; Wiecek A; J Nephrol; 2008; 21(4):592-603. PubMed ID: 18651551 [TBL] [Abstract][Full Text] [Related]
11. A predictive algorithm for the management of anaemia in haemodialysis patients based on ESA pharmacodynamics: better results for less work. Lines SW; Lindley EJ; Tattersall JE; Wright MJ Nephrol Dial Transplant; 2012 Jun; 27(6):2425-9. PubMed ID: 22207330 [TBL] [Abstract][Full Text] [Related]
12. Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13. Birnie K; Caskey F; Ben-Shlomo Y; Sterne JA; Gilg J; Nitsch D; Tomson C Nephrol Dial Transplant; 2017 Apr; 32(4):692-698. PubMed ID: 27190350 [TBL] [Abstract][Full Text] [Related]
13. UK Renal Registry 16th annual report: chapter 10 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2012: national and centre-specific analyses. Rao A; Gilg J; Williams A Nephron Clin Pract; 2013; 125(1-4):183-208. PubMed ID: 24662174 [TBL] [Abstract][Full Text] [Related]
14. It's time to compare anemia management strategies in hemodialysis. Coyne DW Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363 [TBL] [Abstract][Full Text] [Related]
15. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients. Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632 [TBL] [Abstract][Full Text] [Related]
16. Comparison of parenteral iron sucrose and ferric chloride during erythropoietin therapy of haemodialysis patients. Wu CJ; Lin HC; Lee KF; Chuang CK; Chen YC; Chen HH Nephrology (Carlton); 2010 Feb; 15(1):42-7. PubMed ID: 20377770 [TBL] [Abstract][Full Text] [Related]
17. The Impact of Lowering Haemoglobin Targets on Patterns of Erythropoiesis-Stimulating Agent Use in Patients on Haemodialysis. Hazara AM; Owen SJ; Bhandari S Blood Purif; 2016; 41(4):287-92. PubMed ID: 26820617 [TBL] [Abstract][Full Text] [Related]
18. Anaemia management protocols in the care of haemodialysis patients: examining patient outcomes. Saunders S; MacLeod ML; Salyers V; MacMillan PD; Ogborn MR J Clin Nurs; 2013 Aug; 22(15-16):2206-15. PubMed ID: 23336392 [TBL] [Abstract][Full Text] [Related]
19. A Randomized Trial of the Impact of Ferric Citrate on Erythropoietin and Intravenous Iron Use in Patients Receiving Dialysis. Block GA; Mizani MR; Broumand V; Newby FD; Erinle A; Arias C; Block M; Brillhart S; Leppink A; Danese M; Dittrich M Am J Nephrol; 2024; 55(5):520-528. PubMed ID: 38972306 [TBL] [Abstract][Full Text] [Related]
20. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia. Majoni SW; Ellis JA; Hall H; Abeyaratne A; Lawton PD Hemodial Int; 2014 Oct; 18(4):740-50. PubMed ID: 24766376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]